Page 86 - Read Online

Shi et al. J Cancer Metastasis Treat 2018;4:47 I http://dx.doi.org/10.20517/2394-4722.2018.32 Page 19 of 19

lesions. Gastroenterology 2014;146:647-51.
115. Clawson GA, Matters GL, Xin P, McGovern C, Wafula E, dePamphilis C, Meckley M, Wong J, Stewart L, D’Jamoos C, Altman N, Imam-
ura Kawasawa Y, Du Z, Honaas L, Abraham T. “Stealth dissemination” of macrophage-tumor cell fusions cultured from blood of patients
with pancreatic ductal adenocarcinoma. PLoS One 2017;12:e0184451.
116. Francis JM, Zhang C-Z, Maire CL, Jung J, Manzo VE, Adalsteinsson VA, Homer H, Haidar S, Blumenstiel B, Pedamallu CS, Ligon AH,
Love JC, Meyerson M, Ligon KL. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer discov-
ery 2014;4:956-71.
117. Bakker B, Taudt A, Belderbos ME, Porubsky D, Spierings DCJ, de Jong TV, Halsema N, Kazemier HG, Hoekstra-Wakker K, Bradley A, de
Bont ESJM, van den Berg A, Guryev V, Lansdorp PM, Colomé-Tatché M, Foijer F. Single-cell sequencing reveals karyotype heterogeneity
in murine and human malignancies. Genome Biol 2016;17:115.
118. Ruiz C, Li J, Luttgen MS, Kolatkar A, Kendall JT, Flores E, Topp Z, Samlowski WE, McClay E, Bethel K, Ferrone S, Hicks J, Kuhn P.
Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. Phys Biol 2015;12:016008.
119. Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO open
2016;1:e000023.
120. Aceto N, Bardia A, Miyamoto David T, Donaldson Maria C, Wittner Ben S, Spencer Joel A, Yu M, Pely A, Engstrom A, Zhu H, Brannigan
Brian W, Kapur R, Stott Shannon L, Shioda T, Ramaswamy S, Ting David T, Lin Charles P, Toner M, Haber Daniel A, Maheswaran S. Cir-
culating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014;158:1110-22.
121. Medler TR, Cotechini T, Coussens LM. Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of
resistance. Trends Cancer 2015;1:66-75.
122. Tran E, Ahmadzadeh M, Lu Y-C, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP,
Rosenberg SA. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 2015;350:1387-90.
123. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE,
Laurencot CM, Steinberg SM, White DE, Dudley ME. Durable complete responses in heavily pretreated patients with metastatic melanoma
using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.
124. Lu Y-C, Zheng Z, Robbins PF, Tran E, Prickett TD, Gartner JJ, Li YF, Ray S, Franco Z, Bliskovsky V, Fitzgerald PC, Rosenberg SA. An ef-
ficient single-cell RNA-seq approach to identify neoantigen-specific T cell receptors. Mol Ther 2018;26:379-89.
125. Rosati E, Dowds CM, Liaskou E, Henriksen EKK, Karlsen TH, Franke A. Overview of methodologies for T-cell receptor repertoire analy-
sis. BMC Biotechnol 2017;17:61.
126. Shitaoka K, Hamana H, Kishi H, Hayakawa Y, Kobayashi E, Sukegawa K, Piao X, Lyu F, Nagata T, Sugiyama D, Nishikawa H, Tanemura A,
Katayama I, Murahashi M, Takamatsu Y, Tani K, Ozawa T, Muraguchi A. Identification of tumoricidal TCRs from tumor-infiltrating lym-
phocytes by single-cell analysis. Cancer Immunology Research 2018;6:378-88.
127. Baitsch L, Fuertes-Marraco SA, Legat A, Meyer C, Speiser DE. The three main stumbling blocks for anticancer T cells. Trends Immunol
2012;33:364-72.
128. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation.
Immunity 2016;44:989-1004.
129. Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer 2016;16:121.
130. Zheng C, Zheng L, Yoo J-K, Guo H, Zhang Y, Guo X, Kang B, Hu R, Huang JY, Zhang Q, Liu Z, Dong M, Hu X, Ouyang W, Peng J, Zhang Z.
Landscape of infiltrating T xells in liver cancer revealed by single-cell sequencing. Cell 2017;169:1342-56.e16.
131. Singer M, Wang C, Cong L, Marjanovic ND, Kowalczyk MS, Zhang H, Nyman J, Sakuishi K, Kurtulus S, Gennert D, Xia J, Kwon JYH,
Nevin J, Herbst RH, Yanai I, Rozenblatt-Rosen O, Kuchroo VK, Regev A, Anderson AC. A distinct gene module for dysfunction uncoupled
from activation in tumor-infiltrating T cells. Cell 2016;166:1500-11.e9.
132. Chung W, Eum HH, Lee H-O, Lee K-M, Lee H-B, Kim K-T, Ryu HS, Kim S, Lee JE, Park YH. Single-cell RNA-seq enables comprehen-
sive tumour and immune cell profiling in primary breast cancer. Nat Commun 2017;8:15081.
133. Najjar YG, Finke JH. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol
2013;3:49.
134. Damuzzo V, Pinton L, Desantis G, Solito S, Marigo I, Bronte V, Mandruzzato S. Complexity and challenges in defining myeloid-derived
suppressor cells. Cytometry Part B: Clinical Cytometry 2015;88:77-91.
135. Grant CR, Liberal R, Mieli-Vergani G, Vergani D, Longhi MS. Regulatory T-cells in autoimmune diseases: challenges, controversies and—
yet—unanswered questions. Autoimmun Rev 2015;14:105-16.
136. Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J, Arora KS, Desai N,
Dahl DM, Sequist LV, Smith MR, Kapur R, Wu C-L, Shioda T, Ramaswamy S, Ting DT, Toner M, Maheswaran S, Haber DA. RNA-Seq of
single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science 2015;349:1351-6.
137. Dago AE, Stepansky A, Carlsson A, Luttgen M, Kendall J, Baslan T, Kolatkar A, Wigler M, Bethel K, Gross ME, Hicks J, Kuhn P. Rapid
phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content snalysis of single circulating
tumor cells. PLoS One 2014;9:e101777.